Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Aurinia PharmaceuticalsAUPH | Open-market buy | 05/29–06/02 | 06/02 | 814,606 sh5 trades | $15.29avg. | $12,455,227.01 | +6.7% | |
Aurinia PharmaceuticalsAUPH | Open-market buy | 05/29–06/02 | 06/02 | 814,606 sh5 trades | $15.29avg. | $12,455,227.01 | +6.7% | |
Aurinia PharmaceuticalsAUPH | Open-market buy | 02/27–03/03 | 03/03 | 900,000 sh6 trades | $14.10avg. | $12,688,805.89 | +7.9% | |
Aurinia PharmaceuticalsAUPH | Open-market buy | 25/08/01–25/08/05 | 25/08/05 | 1,300,000 sh3 trades | $10.45avg. | $13,590,000 | +13.0% | |
Greg KeenanChief Medical Officer | Aurinia PharmaceuticalsAUPH | Open-market sale | 25/08/01 | 25/08/05 | 20,000 sh | $10.50 | $210,000 | −13.0% |
Greg KeenanChief Medical Officer | Aurinia PharmaceuticalsAUPH | Open-market sale | 25/03/07 | 25/03/07 | 8,305 sh | $8.23 | $68,350.15 | −5.1% |
Aurinia PharmaceuticalsAUPH | Open-market buy | 25/02/28–25/03/04 | 25/03/04 | 1,600,000 sh6 trades | $7.95avg. | $12,713,125.64 | +19.0% | |
Aurinia PharmaceuticalsAUPH | Open-market sale | 25/03/03–25/03/04 | 25/03/04 | 360,540 sh2 trades | $7.96avg. | $2,871,124.24 | −16.8% | |
Aurinia PharmaceuticalsAUPH | Open-market sale | 25/03/03–25/03/04 | 25/03/04 | 124,893 sh2 trades | $7.96avg. | $994,424.72 | −15.5% | |
Aurinia PharmaceuticalsAUPH | Open-market sale | 25/03/03–25/03/04 | 25/03/04 | 118,013 sh2 trades | $7.96avg. | $939,611.68 | −17.0% | |
Aurinia PharmaceuticalsAUPH | Open-market sale | 25/03/03–25/03/04 | 25/03/04 | 122,479 sh2 trades | $7.96avg. | $975,223.44 | −19.4% | |
Greg KeenanChief Medical Officer | Aurinia PharmaceuticalsAUPH | Open-market sale | 25/03/03 | 25/03/04 | 12,239 sh | $8.00 | $97,912 | −7.0% |
Aurinia PharmaceuticalsAUPH | Open-market buy | 24/12/05–24/12/09 | 24/12/09 | 1,200,000 sh3 trades | $9.02avg. | $10,822,000 | +16.6% | |
Jeffrey Allen BaileyDirector | Aurinia PharmaceuticalsAUPH | Open-market sale | 24/11/11 | 24/11/12 | 4,557 sh | $8.43 | $38,415.51 | −25.4% |
Karen L. SmithDirector | Aurinia PharmaceuticalsAUPH | Open-market sale | 24/11/11 | 24/11/12 | 5,241 sh | $8.43 | $44,181.63 | −29.3% |
Scott Michael HabigChief Commercial Officer | Aurinia PharmaceuticalsAUPH | Open-market sale | 24/08/06 | 24/08/08 | 18,249 sh | $5.31 | $96,902.19 | −3.8% |
Jill LeversageDirector | Aurinia PharmaceuticalsAUPH | Open-market sale | 24/05/21 | 24/05/22 | 5,610 sh | $5.74 | $32,201.4 | −30.3% |
Daniel BillenDirector | Aurinia PharmaceuticalsAUPH | Open-market sale | 24/05/21 | 24/05/22 | 5,252 sh | $5.74 | $30,146.48 | −15.7% |
David R.W. JayneDirector | Aurinia PharmaceuticalsAUPH | Open-market sale | 24/05/21 | 24/05/22 | 4,946 sh | $5.74 | $28,390.04 | −10.0% |
R. Hector MacKay-DunnDirector | Aurinia PharmaceuticalsAUPH | Open-market sale | 24/05/21 | 24/05/22 | 5,630 sh | $5.74 | $32,316.2 | −23.2% |